A new cryptic CFTR exon in mild CF  by Costa, C. et al.
S2 1. Genetics
5 A new cryptic CFTR exon in mild CF
C. Costa1,2, V. Prulie`re-Escabasse3, L. Bassinet4, L. Golmard2, C. Gameiro1,
A. de Becdelie`vre1,2, M. Goossens1,2, E. Girodon1,2. 1Ge´ne´tique, CHU H
Mondor, Cre´teil, France; 2Ge´ne´tique, INSERM U955 e´quipe 11, Cre´teil, France;
3ORL, CHU H Mondor, Cre´teil, France; 4Pneumologie-CRCM, CHI, Cre´teil,
France
So far, over 1500 CFTR gene mutations have been described responsible for
CF and CFTR-related disorders. Screening for large gene rearrangements has
improved identiﬁcation of CF alleles but a number of cases remain unsolved,
making genetic counselling difﬁcult, particularly when the diagnosis is uncertain. It
has been hypothetised that unidentiﬁed CF mutations may lie in introns which
are not routinely investigated. Such events have been rarely reported, such as
3849+10kbC>T and 1811+1.6kbA>G.
We report the case of a French 25 y woman diagnosed at 4 y with disseminated
bronchiectasis, pancreatic sufﬁciency and borderline sweat tests. Screening of the
27 exons including search for gene rearrangements only identiﬁed F508del in
heterozygosity. Investigation at the mRNA level was then performed from nasal
epithelial cells.
An abnormal, longer CFTR mRNA was detected, corresponding to a 97bp insert
between exons 6b and 7. This fragment matches a 101bp sequence of intron 6b
deleted of 4bp, which starts 1061bp upstream exon 7 and is ﬂanked by the consensus
donor and acceptor splice sites. A new stop codon is created within the inserted
sequence. The amount of abnormal CFTR mRNA of the patient was estimated to
be 20% of the wild type, which suggests the abnormal splicing is due to partial
activation of a cryptic splice site whose impact could be considered as mild. This
hypothesis is supported by the fact that the patient does not suffer from severe CF.
Studies at the genomic level are still ongoing to identify the mutation which leads
to the partial activation of a cryptic splice site and explains the creation of a new
exon.
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Owing to the steadily increasing number of requests for CF genetic testing, it is
impossible providing classic genetic counselling sessions to all who want the test.
This study evaluates the performance of a recently developed interactive multimedia
software, designed to be a decision aid for CF genetic testing potential users. Twenty
ﬁve participants (21M 4F) were recruited by Clinical Genetics Services in Verona
and Milan. They were included in either group GC where education was provided
by a Genetic Counsellor (7 individuals), or in group IC, where education was
provided by the Interactive Computer programme (18 individuals). Both groups
were assessed by a 10 question multiple-choice questionnaire before and after
the counsellor/computer session, and the results evaluated by a two-sample t-test.
Average correct answers raised from 3.71/10 before the information to 9.57/10
after the information in group GC (p 0.001), and from 4.17/10 to 9.22/10 in group
IC (p< 0.0001); wrong answers decreased from 1.86/10 before the information
to 0.43/10 after the information in group GC (n.s.), and from 2.06/10 to 0.78/10
in group IC (p 0.008); “don’t know” answers changed from 4.43/10 before the
information to 0/10 after the information in group GC, and from 3.78/10 to 0/10
in group IC. These preliminary results show that a multimedia programme may
perform at least as well as traditional individual genetic counselling in promoting
understanding about CF genetic testing.
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The French CF Laboratory Network, composed of 35 molecular genetics labora-
tories and which settlement had been facilitated by the European CF Network,
was recognized seven years ago by the French Ministry of Health. Ten of the
laboratories received ﬁnancial support for in-depth CFTR gene molecular analysis
and a subgroup of four had additional support for management of the Network and
CF clinical research.
Based on best practices guidelines for CFTR gene analysis, DNA samples may be
processed in one or two different laboratories, depending on the indication of the
test and the laboratories’ level of expertise. More than 10,000 samples are studied
per year (50–1500 per lab) including 200 prenatal diagnoses. The continuous share
of experience on rare variants greatly helps genetic counselling.
Since 2001, six workshops were organized, convening molecular geneticists, tech-
nicians, clinicians of CF care centres and private companies. Three main topics
were addressed: (1) Network functioning, discussion on best practice guidelines and
report on European actions; (2) technical points including new technologies; (3) and
clinical issues. A number of collaborative studies have been published and others
are still ongoing, such as the spectrum of mutations in CF and CBAVD in France;
the CFTR genotypes in patients with normal/borderline sweat tests; the incidence
of CF in fetal bowel anomalies; or phenotype-genotype correlations on R117H.
The active involvement of the molecular geneticists of specialized laboratories in
European actions greatly contributes to the dynamism of the French Network.
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New generation sequencing technology has been recently introduced. However, this
technology was initially developed for whole genome sequencing purposes.
We have adopted this technology for complete sequence analysis of the CFTR
coding region, and its exon/intron junctions.
For a 50x coverage, only half a million nucleotides are needed for CFTR sequence
analysis, i.e. 0.5% of the full capacity of the GS-FLX system. Therefore, 100–
200 samples should be pooled in order to use the full capacity of the GS-FLX
system. We have developed an economically feasible universal sample tagging
approach allowing the pooling of 100 samples with one set of 260 primers. This
compares to 6000 primers if amplicon-speciﬁc PCR primers are tagged as such.
Normally, each amplicon should be ampliﬁed individually and puriﬁed, after which
the concentration of each solution is accurately determined, and an equimolar
amplicon mixture is prepared for sequencing. The universal tagging approach
resulted in a less dynamic range of the yield of the different amplicon products, so
that the preparation of the equimolar amplicon mixture is simpliﬁed.
We are even further simplifying the PCR reactions through the development of
robust multiplex PCR reactions. Indeed, 30 amplicons should be analyzed for the
CFTR gene, and this can ultimately be only economically feasible if ampliﬁed
in one, or a limited number, of multiplex PCR reaction(s). Speciﬁcally we have
developed a robust multiplex ampliﬁcation assay in which biotinylated amplicon-
speciﬁc primers are locally restricted through streptavidin/biotin crosslinking.
We thus developed an assay for routine sequencing of the CFTR gene in a diagnostic
setting by next generation sequencing. Moreover, this assay is readily transferable
to any gene.
